Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.78
    -0.08 (-4.30%)

    Market Cap: $60.87M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Insight Molecular Diagnostics Inc. (IMDX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Insight Molecular Diagnostics (IMDX) has a market cap of $60.87M and an enterprise value of $51.25M. It kept -2137.33% of revenue as net income over the last 12 months. Its share count is up 15.08% from a year earlier.

    Total Valuation

    Enterprise value is 15.80% below the market cap, as cash exceeds debt.

    Market Cap$60.87M
    Enterprise Value$51.25M
    Latest price (Nov 17, 2026)$1.78

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and grew 64.67% a year over 3 years.

    Shares Outstanding36.86M
    Shares Change (YoY)+15.08%
    Shares Change (QoQ)+0.31%
    Share Count Growth (3Y CAGR)+64.67%

    Valuation Ratios

    The price to sales ratio is 33.3x. Its year-end P/S ranged from 19.3x to 131.8x from 2020 to 2025.

    P/S Ratio33.3x
    Forward P/S63.0x

    Price Statistics

    The stock is down 75.95% over 52 weeks and trades 44.38% below its 50-day average.

    Beta (1Y)2.64
    52-Week Change-75.95%
    1-Month Change-38.41%
    3-Month Change-59.36%
    6-Month Change-67.99%
    5-Year Change-95.49%
    10-Year Change-96.35%
    Total Return (1Y)-75.95%
    Total Return (3Y CAGR)-24.21%
    Total Return (5Y CAGR)-49.96%
    Return vs SPY (1Y)-83.44%
    Max Drawdown (1Y)-76.27%
    Max Drawdown (3Y)-79.01%
    Sharpe Ratio (1Y)-1.19
    Correlation with SPY (1Y)0.34
    50-Day Average$3.20
    200-Day Average$4.48
    52-Week Range$1.85 to $7.51
    RSI (14 Days)20.7
    Average Volume (20 Days)203.63K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.46x current liabilities.

    Current Ratio1.46x
    Quick Ratio1.42x
    Interest Coverage-488.35x

    Returns and Efficiency

    Return on invested capital is 145.71% over the last 12 months, against a 5-year average of 134.91%.

    Return on Assets (ROA)-193.56%
    Return on Invested Capital (ROIC)145.71%
    Return on Capital Employed (ROCE)-343.43%
    ROIC (5Y Average)134.91%
    Asset Turnover0.06x
    Inventory Turnover3.08x
    Receivables Turnover5.53x
    Cash Conversion Cycle-814 days

    Scores

    IMDX has an Altman Z-Score of -32.22, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-32.22
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $1.97M over the last 12 months is down 55.27% from the 12 months before.

    Revenue$1.97M
    Revenue Growth (YoY)-55.27%
    Gross Profit$1.08M
    Operating Income-$42.93M
    Pretax Income-$42.08M
    Net Income-$42.08M
    EBITDA-$39.50M
    EBIT-$42.00M
    Reported EPS (TTM)-$1.26

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$11.02M
    Total Debt$1.41M
    Net Cash$9.62M
    Net Cash Per Share$0.26
    Working Capital$4.37M
    Shareholder Equity-$24.18M
    Total Assets$21.74M
    Total Liabilities$45.92M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $3.71M of capital spending, operating cash flow left -$32.60M of free cash flow.

    Operating Cash Flow-$28.89M
    Capital Expenditures$3.71M
    Free Cash Flow-$32.60M
    FCF Per Share-$1.00
    Depreciation and Amortization$2.50M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2180.09%.

    Gross Margin54.65%
    Operating Margin-2180.09%
    Pretax Margin-2137.33%
    Net Margin-2137.33%
    EBITDA Margin-2005.94%
    EBIT Margin-2132.96%
    FCF Margin-1655.51%
    Gross Margin (5Y Average)37.24%

    Growth

    Revenue grew 61.76% a year over 3 years.

    Revenue Growth (3Y CAGR)+61.76%
    Revenue Growth (5Y CAGR)+27.24%

    Revenue and profit by year

    Dividends and Yields

    IMDX does not pay a dividend. Its free cash flow yield is -49.68%.

    FCF Yield-49.68%
    Buyback Yield-37.56%
    Shareholder Yield-37.56%

    Stock Splits

    The last split was a 1-for-20 reverse split on Jul 25, 2023.

    Last Split DateJul 25, 2023
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 9 similar companies, IMDX has the 2nd highest P/S.

    P/S Ratio33.3x vs 2.4x median
    ROIC145.71% vs -23.27% median
    Revenue Growth (Trailing 4 Quarters, YoY)-55.27% vs +17.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 28.18% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+28.18%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IMDX

    What is IMDX's market cap?

    Insight Molecular Diagnostics has a market cap of $60.87M. Its enterprise value, which adds debt and subtracts cash, is $51.25M.

    How many shares of IMDX are outstanding?

    Insight Molecular Diagnostics has 36.86M shares outstanding. The count is up 15.08% from a year earlier.

    Does IMDX pay a dividend?

    No. Insight Molecular Diagnostics does not pay a dividend.

    How much debt does IMDX have?

    Insight Molecular Diagnostics has $1.41M of total debt and $11.02M of cash and equivalents, a net cash position of $9.62M.